Work

Fri0120 High Levels of Interleukin-6 (il-6) in Ra Patients Are Associated With Greater Improvements in Patient-reported Outcomes (pros) for Sarilumab Compared With Adalimumab

Year: 2019

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2019-eular.3294

Authors: Vibeke Strand, Susan Boklage, Toshio Kimura, Florence Joly, Anita Boyapati, Jérôme Msihid

Institutions: Stanford University, Regeneron (United States), Sanofi (France)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Amgen, Eli Lilly and Company, Pfizer, Sanofi, Celgene, Regeneron Pharmaceuticals, Celltrion, Servier, Genentech, Samsung, EMD Serono

OpenAlex ID: W2951594253

Cites:

Cited by: 1

Related to: 10